RY764 is a potent and selective melanocortin subtype-4 receptor agonist.

AZD4320 is a novel, potent BH3-mimic and dual inhibitor of BCL2/BCLxL with IC50s of 26 nM, 17 nM, and 170 nM for KPUM-MS3, KPUM-UH1, and STR-428 cells, respectively.

TW-37 (TW37 or TW 37) is a novel and potent small-molecule inhibitor of Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.

S63845 TFA, the Trifluoroacetic acid salt of S63845, is a potent, selective small molecule inhibitor of MCL1 (myeloid cell leukemia 1) with Ki value < 1.2 nM.

DT2216 (DT-2216; DT 2216) is a novel and potent degrader of B-cell lymphoma extra large (BCL-XL) based on proteolysis-targeting chimera (PROTAC) technology.

ABT-737 is a novel, potent, selective and orally bioavailable BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in enzymatic assays, respectively. It does not inhibit Mcl-1, Bcl-B or Bfl-1 etc.

MIK665 (also known as MIK-665; S-64315) is a novel, investigational and specific Mcl-1 inhibitor with an IC50 of 1.81 nM.

AZD-5991 racemate, the racemate of AZD5991, is a Mcl-1 inhibitor (IC50<3 nM in FRET assay) with antitumor activity.

Obatoclax Mesylate (also known as GX15 070), the mesylate salt of obatoclax, is a potent inhibitor of Bcl-2 (B-cell leukemia protein-2) protein with a Ki of 0.22 μM in a cell-free assay.

AZD-5991 (AZD5991) is a novel, potent, rationally designed macrocyclic molecule and selective MCL-1 inhibitor with anticancer activity.